Related party transactions - Disclosure of transactions between related parties (Details) € in Thousands |
6 Months Ended |
|---|---|
|
Jun. 30, 2026
EUR (€)
| |
| AstraZeneca | |
| Disclosure of transactions between related parties [Line Items] | |
| Collection | € 751 |
| Receivables | 230 |
| Payments | |
| Liabilities | (39,612) |
| Net collection (payments) | 751 |
| Net receivables (liabilities) | (39,382) |
| Sanofi-Aventis | |
| Disclosure of transactions between related parties [Line Items] | |
| Collection | 0 |
| Receivables | 0 |
| Payments | 0 |
| Liabilities | 0 |
| Net collection (payments) | 0 |
| Net receivables (liabilities) | € 0 |
| X | ||||||||||
- Definition The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow from advances and loans from related parties. [Refer: Total for all related parties [member]] Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]] Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. No definition available.
|
| X | ||||||||||
- Definition The net amounts of receivables (payable) resulting from related party transactions. No definition available.
|
| X | ||||||||||
- Definition Net Cash Advance Received From (Made To) Related Parties No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|